Cyclosporine A (CsA) is an immunosuppressant that is efficacious in se
veral inflammatory skin disorders. Its use is, however, limited due to
systemic side-effects. Topical forms of CsA have been tried but they
do not seem to be effective presumably due to insufficient penetration
to skin. Tacrolimus (FK506) is another immunosuppressant that has alm
ost similar effects on the cellular level as CsA. FK506 is 10-100 time
s more potent than CsA and it has lower molecular weight. Recent studi
es suggest that topical FK506 penetrates human skin in amounts exceedi
ng those of topical CsA. Topical FK506 also seems to suppress skin inf
lammation in man. These findings prompt for further clinical studies o
f efficacy and safety of topical FK506.